Over 25 pharma firms advance 30+ PARP inhibitors in clinical trials for cancer treatment.

More than 25 pharmaceutical companies are actively developing over 30 PARP inhibitor drugs, targeting cancers like breast, prostate, and solid tumors. These drugs work by blocking DNA repair in cancer cells, leading to cell death, especially in tumors with BRCA mutations. Key players include AstraZeneca, Gilead Sciences, and others, with several drugs in various trial phases from preclinical to Phase III. The growing focus on precision medicine and combination therapies is driving adoption, despite challenges like high costs and resistance.